Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: A cost-effectiveness analysis

Cancer

Volumn 80, Issue 6, 1997, Pages 1052-1064

  Mooney, Margaret M ^a   Mettlin, Curtis ^a   Michalek, Arthur M ^a   Petrelli, Nicholas J ^a   Kraybill, William G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cost benefit analysis; Cost effectiveness; Melanoma; Neoplasm; Recurrence

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER SCREENING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; LUNG METASTASIS; MELANOMA; MODEL; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

AGED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS CHEST X-RAY; MELANOMA; MIDDLE AGED; POPULATION SURVEILLANCE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS;

EID: 0030766196     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970915)80:6<1052::AID-CNCR7>3.0.CO;2-B     Document Type: Article

References (45)

1. American Cancer Society. Cancer facts and figures - 1996. Atlanta: American Cancer Society, 1996.
2. Martini L, Brandani P, Chiarugi C, Reali U. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori 1994;80:188-97.
3. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91:94-8.
4. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance: patient or physician based? Ann Surg 1995;221: 566-71.
5. Yeung RSW. Recurrent cutaneous melanoma: a surgical perspective. Semin Oncol 1993;20:400-18.
6. Soong S-J, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16:191-5.
7. Slingluff CL, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression: implications for the concept of cure. Cancer 1992;70:1917-27.
8. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg 1990;212:173-7.
9. Tahery DP, Moy RL. Recurrent malignant melanoma following a 35-year disease-free interval. J Dermatol Surg Oncol 1993;19:161-3.
10. Pearlman NW, Takach TJ, Robinson WA, Ferguson J, Cohen AL. A case-control study of late recurrence of malignant melanoma. Am J Surg 1992;164:458-61.
11. Romero JB, Stcfanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma. J Dermtol Surg Oncol 1994;20:175-8.
12. Weiss M, Loprinzi CL, Greagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274:1703-5.
13. Bassères N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, et al. Cost-effectiveness of surveillance of stage I melanoma: a retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995;191:199-203.
14. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: J.B. Lippincott Company, 1992:143-5.
15. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-58.
16. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-54.
17. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. JAMA 1992: 267:2055-61.
18. Wong JB, Koff RS, Tinè F, Pauker SG. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995:122:664-75.
19. Fabian R. The qualy approach. In: Tolley G, Kenkel D, Fabian R, editors. Valuing health for policy: an economic approach. Chicago: University of Chicago Press, 1994:118-36.
20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996:276:1253-8.
21. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK, editors. SEER Cancer Statistics Review, 1973-1992: Tables and Graphs [CD-ROM Public Access File]. Bethesda (MD): National Cancer Institute; 1995 NIH Pub. No. 96-2789.
22. Singh CK, Kochanek KD, MacDorman MF. Advance report of final mortality statistics, 1994. Monthly Vital Statistics Report. Hyattsville, (MD): National Center for Health Statistics; 1996 DHHS Pub. No. (PHS) 96-1120.
23. Colton T. Statistics in medicine. 1st edition. Boston: Little, Brown and Company, 1974.
24. Troell RJ, Terris DJ. Detection of metastases from head and neck cancers. Laryngoscope 1995;105:247-50.
25. Houghton AN, Balch CM. Treatment for advanced melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, editors. Cutaneous melanoma. 2nd edition. Philadelphia: J.B. Lippincott Company, 1992:468-97.
26. Pogrebniak HW, Stovroff M, Roth JA, Pass HI. Resection of pulmonary metastases from malignant melanoma:results of a 16-year experience. Ann Thorac Surg 1988:46:20-3.
27. Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary metastasis: a 20-year experience. Ann Thorac Surg 1984;38:323-30.
28. Karp NS, Boyd A, DePan HJ, Harris MN, Roses DF. Thoracotomy for metastatic malignant melanoma of the lung. Surgery 1990;107:256-61.
29. Harpole DH, Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992;103:743-50.
30. Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995;110:119-29.
31. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 1994; 271:1587-92.
32. Kattlove H, Liberati A, Keeler E, Brook RH. Benefits and costs of screening and treatment for early breast cancer: development of a basic benefit package. JAMA 1995;273:142-8.
33. DiMarco AF, Briones B. Is chest CT performed too often? Chest 1993;103:985-6.
34. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995;13:2094-103.
35. Colice GL, Birkmeyer JD, Black WC, Littenberg B, Silvestfi G. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest 1995;108: 1264-71.
36. Hazelrigg SR, Nunchuck SK, Landreneau RJ, Mack MJ, Naunheim KS, Seifert PE, et al. Cost analysis for thoracoscopy: thoracoscopic wedge resection. Ann Thorac Surg 1993;56:633-5.
37. Black WC, Armstrong P, Daniel TM. Cost effectiveness of chest CT in T1N0M0 lung cancer. Radiology 1988;167:373-8.
38. Luce BR, Simpson K. Methods of cost-effectiveness analysis: areas of consensus and debate. Clin Ther 1995;17:109-25.
39. U.S. Bureau of the Census. Statistical abstract of the United States: 1995. 115th edition. U.S. Bureau of the Census, Washington, DC, 1995.
40. Folland S, Goodman AC, Stano M. The economics of health and health care. New York: Macmillan Publishing Company, 1993:638-9.
41. Lave LB. Benefit-cost analysis: do the benefits exceed the costs? In: Hahn RW, editor. Risks, costs, and lives saved: getting better results from regulation. New York: Oxford University Press, 1996:104-34.
42. Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination. JAMA 1996;276:285-92.
43. Frame PS, Frybach DG, Patterson C. Screening for abdominal aortic aneurysm in men ages 60 to 80. Ann Intern Med 1993;119:411-6.
44. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med 1990;112:192-202.
45. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348: 150-4.